Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie Acquires 10,500 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie acquired 10,500 shares of the business’s stock in a transaction on Wednesday, February 19th. The stock was acquired at an average price of $5.51 per share, with a total value of $57,855.00. Following the transaction, the chief financial officer now directly owns 10,500 shares of the company’s stock, valued at $57,855. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Septerna Trading Down 1.5 %

SEPN opened at $5.80 on Friday. Septerna, Inc. has a 52 week low of $4.17 and a 52 week high of $28.99. The firm’s fifty day moving average is $17.78.

Analyst Ratings Changes

Several research analysts have issued reports on SEPN shares. Wells Fargo & Company cut Septerna from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $43.00 to $14.00 in a research report on Tuesday. JPMorgan Chase & Co. started coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target for the company. TD Cowen started coverage on Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $50.00 price target on shares of Septerna in a research report on Tuesday, February 11th.

Institutional Trading of Septerna

Large investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC acquired a new stake in shares of Septerna during the fourth quarter valued at $25,000. New York State Common Retirement Fund acquired a new stake in shares of Septerna during the fourth quarter valued at $32,000. Legal & General Group Plc acquired a new stake in shares of Septerna during the fourth quarter valued at $42,000. Summit Investment Advisors Inc. acquired a new stake in shares of Septerna during the fourth quarter valued at $45,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Septerna during the fourth quarter valued at $52,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.